Medicaid Now Covers GLP-1s for Obesity in Georgia

Photo Credit: Nito / Shutterstock

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the government’s role in subsidizing access to these drugs. Originally developed for Type 2 diabetes, these medications have proven highly effective for treating obesity—a chronic condition affecting more than 40% of U.S. adults. However, with costs often exceeding $1,000 per month for patients who are under- or uninsured, these treatments remain out of reach for many Americans.

Medicare currently limits its coverage of GLP-1s to individuals with Type 2 diabetes or certain heart conditions, excluding prescriptions aimed solely at obesity. Medicaid coverage of GLP-1s for obesity, however, varies by state. While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).

Recommended for you

Originally published on realchemistry.com, part of the BLOX Digital Content Exchange.

(0) comments

Welcome to the discussion.

Please log in, or sign up for a new, free account to read or post comments.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.